HER2-POSITIVE BREAST CARCINOMA
Clinical trials for HER2-POSITIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control CompletedThis phase 2 trial tests a new drug called TVB-2640 (denifanstat) combined with trastuzumab and either chemotherapy (paclitaxel) or hormone therapy in 17 people with HER2+ metastatic breast cancer that no longer responds to trastuzumab. TVB-2640 blocks an enzyme cancer cells need…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Custom vaccine shows promise in targeting aggressive breast cancer
Disease control CompletedThis early-phase study tested a vaccine made from patients' own immune cells to target HER2-positive breast cancer. 31 participants with stage II or III breast cancer received the vaccine alongside standard chemotherapy before surgery. The goal was to see if the vaccine could boo…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo aims to stop breast cancer return after surgery
Disease control CompletedThis phase II study tested a combination of two chemotherapy drugs (cyclophosphamide and paclitaxel) plus the targeted drug trastuzumab given after surgery to 20 patients with early-stage HER2-positive breast cancer. The goal was to see if this regimen is safe and can help preven…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC